Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Tabata, N. Hirayama, A. Yasumitsu, S. Yamada, A. Murakami, K. Tamura, T. Terada, K. Kuribayashi, K. Fukuoka, T. Nakano (Nishinomiya, Japan). All-trans-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice. Eur Respir J 2010; 36: Suppl. 54, 3854

Member's Comments

No comment yet.

Related content which might interest you: All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice Source: Eur Respir J 2009; 34: 1159-1167 Year: 2009 mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 Osteopontin of either host or tumor origin critically affects malignant pleural effusion formation Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Malignant pleural effusion cells show aberrant glucose metabolism gene expression Source: Eur Respir J 2011; 37: 1453-1465 Year: 2011 The value of IL6 in differentiation between malignant and non malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 CXCL12 expression in malignant mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 138s Year: 2007 Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma Source: Eur Respir J 2008; 32: 924-930 Year: 2008 PET predicts survival in malignant pleural mesothelioma Source: ISSN=ISSN 1810-6838, ISBN=, page=290 Year: 2007 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Comparison of telomerase activity in malignant and benign pleural effusions Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007 Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 The radiologic evidance in distinguishing the pleural mesothelioma from the pleural metastatic adenocarcinoma Source: Eur Respir J 2006; 28: Suppl. 50, 93s Year: 2006 RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012 Multimodality treatment of malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 ADAM10 membrane-bound protease mediates malignant pleural mesothelioma invasiveness Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management Year: 2018